Nebula Research & Development LLC Takes $697,000 Position in Cellebrite DI Ltd. (NASDAQ:CLBT)

Nebula Research & Development LLC purchased a new position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 31,645 shares of the company's stock, valued at approximately $697,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lord Abbett & CO. LLC lifted its holdings in Cellebrite DI by 6.7% during the 4th quarter. Lord Abbett & CO. LLC now owns 730,339 shares of the company's stock worth $16,089,000 after buying an additional 46,119 shares in the last quarter. Oberweis Asset Management Inc. raised its position in Cellebrite DI by 1.2% in the 4th quarter. Oberweis Asset Management Inc. now owns 692,910 shares of the company's stock valued at $15,265,000 after purchasing an additional 8,100 shares in the last quarter. Axon Enterprise Inc. acquired a new position in shares of Cellebrite DI during the fourth quarter worth about $198,270,000. OneDigital Investment Advisors LLC purchased a new stake in shares of Cellebrite DI during the fourth quarter worth approximately $615,000. Finally, State of Tennessee Department of Treasury raised its holdings in Cellebrite DI by 7.6% in the fourth quarter. State of Tennessee Department of Treasury now owns 180,175 shares of the company's stock valued at $3,969,000 after acquiring an additional 12,755 shares in the last quarter. Hedge funds and other institutional investors own 45.88% of the company's stock.

Analysts Set New Price Targets

CLBT has been the subject of a number of recent analyst reports. JPMorgan Chase & Co. lifted their price target on Cellebrite DI from $24.00 to $28.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Needham & Company LLC reaffirmed a "buy" rating and issued a $28.00 target price on shares of Cellebrite DI in a report on Wednesday, April 2nd. Finally, Lake Street Capital increased their price target on shares of Cellebrite DI from $17.00 to $26.00 and gave the stock a "buy" rating in a research note on Friday, February 14th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $23.43.

Cellebrite DI Stock Up 1.4 %

Shares of NASDAQ CLBT traded up $0.28 during mid-day trading on Friday, hitting $20.14. 762,064 shares of the company were exchanged, compared to its average volume of 1,421,025. The firm has a market cap of $4.82 billion, a price-to-earnings ratio of -14.49, a price-to-earnings-growth ratio of 4.27 and a beta of 1.44. The stock has a 50 day simple moving average of $18.82 and a 200-day simple moving average of $20.20. Cellebrite DI Ltd. has a 1-year low of $10.25 and a 1-year high of $26.30.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last released its earnings results on Thursday, February 13th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a positive return on equity of 58.70% and a negative net margin of 70.54%. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 earnings per share for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.